L ess than 50% of hypertensive patients in the United States have their blood pressure (BP) under control. These numbers worsen in older women. Furthermore, hypertension is more common in young males when compared with premenopausal females, a difference that disappears after menopause. 1 Indeed, premenopausal women are protected from cardiovascular diseases (CVD) while postmenopausal women have the same risk for these diseases, as do men. However, women seem to be at greater risk than men for developing hypertension-related CVD, that is, heart failure with preserved ejection fraction-a condition with limited effective treatment options. Thus, understanding the mechanisms driving disordered BP control and its outcomes in males and females may lead to more personalized and targeted therapy to effectively and better control BP and reduce adverse cardiovascular outcomes.
L ess than 50% of hypertensive patients in the United States have their blood pressure (BP) under control. These numbers worsen in older women. Furthermore, hypertension is more common in young males when compared with premenopausal females, a difference that disappears after menopause. 1 Indeed, premenopausal women are protected from cardiovascular diseases (CVD) while postmenopausal women have the same risk for these diseases, as do men. However, women seem to be at greater risk than men for developing hypertension-related CVD, that is, heart failure with preserved ejection fraction-a condition with limited effective treatment options. 2 Thus, understanding the mechanisms driving disordered BP control and its outcomes in males and females may lead to more personalized and targeted therapy to effectively and better control BP and reduce adverse cardiovascular outcomes.
One such mechanistic pathway is the renin-angiotensinaldosterone system (RAAS). This system plays a critical role in BP regulation both via its effect on sodium and volume homeostasis and vascular reactivity and structure. For example, there is abundant evidence showing that in humans and rodents, chronic activation of the mineralocorticoid receptor (MR) and disordered angiotensin II (AngII) and aldosterone levels lead to an increase in BP and cardiovascular and renal damage. However, the impact of biological sex on RAAS activation is controversial. Early reports showed that plasma renin activity (PRA) was higher in men than in women regardless of age and ethnic heritage. 3, 4 Of interest, there are reports showing that men and women have similar mean BP responses to acute AngII infusion. [5] [6] [7] In contrast, more recent studies showed that men had greater diastolic and mean BP responses to acute AngII than did women. 8 Inconsistencies on aldosterone levels among men and women also have been observed. For example, women from the Framingham Offspring Study showed higher aldosterone levels than did men. 9 Aldosterone levels in women are associated with changes in the estrous cycle. There is evidence that aldosterone levels are higher in women than men during the luteal phase of the menstrual cycle but not during the periovulatory period or during menses. 10 Indeed, aldosterone secretion rates during the follicular phase were comparable to those in men but significantly increased during the luteal phase in women. 11 However, these studies did not control for sodium intake or posture, major influences on RAAS activity. In contrast, Miller et al 6 reported plasma aldosterone levels that were lower in women than men on a liberal sodium (200 mmol) intake that were measured while subjects were supine. However, these women had a greater increase in aldosterone response to AngII infusion than men. Ruilope et al 12 reported opposite results: women had a greater aldosterone response to upright posture than did men, again with dietary salt controlled. Interestingly, these investigators did not find any difference in PRA responses to standing up. Reports by members of our group have shown that aldosterone levels are higher during the luteal phase on high-but not low-sodium balance whereas renin and AngII do not differ between phases. 13 Furthermore, Katz et al 14 reported that plasma aldosterone levels were higher in women than in men on restricted sodium diets without control for phase of the menstrual cycle. Finally, in a small population, we reported that aldosterone responses to AngII were greater in women than men with hypertension and likely familially associated. 15, 16 This difference narrows in older subjects and is likewise not observed in hypertensives of African descent. 17 Thus, there remains controversy on the relationships between biological sex, aldosterone/MR activation, and cardiovascular damage. In part, the reported discrepancies are likely secondary to small sample sizes and failure to control for environmental factors, such as salt intake, posture, and time of day, that have important effects on RAAS activity.
To address this controversy, we hypothesized that females, regardless of menopausal and disease status, will have greater salt sensitivity of BP than men and that the primary mechanism underlying this difference is altered aldosterone production. We used 2 approaches to test this hypothesis. First, we studied a large cohort of subjects participating in the Hypertensive Pathotype (HyperPATH) consortium where subjects are well characterized and environmental, menopausal state, and dietary factors that can affect aldosterone and BP are tightly controlled. [18] [19] [20] We contrasted AngII-stimulated aldosterone levels and salt sensitivity of BP in women and men. Second, we assessed sex differences in a chronic rodent model that produces vascular and renal damage in response to increased AngII and low NO levels and characterized the effects of MR blockade on these injuries. These comparative studies of male and female rats allowed for sex-based analyses of AngII function and vascular damage in a model of chronic MR activation.
Methods

HyperPATH Cohort and Study Protocol
Our studies were performed on extensively characterized subjects from the HyperPATH consortium. This is an ongoing study aimed at investigating the pathophysiologic and genotypic mechanisms involved in hypertension and CVD that has been previously described. [18] [19] [20] We studied 1592 individuals (682 women and 910 men), with similar protocols ( Figure S1 in the online-only Data Supplement). The Human Subjects Committees approved these protocols, and informed written consent was obtained from each subject. Subjects were consented well before the development of guidelines to promote openness. Therefore, requests for select deidentified study data and analytic methods will be considered on a case-by-case basis from qualified researchers with institutional review board approvals and executed institutional data transfer agreements. The data set will be available from Dr Gordon H. Williams, Principal Investigator for the HyperPATH consortium, by e-mail request (gwilliams@bwh.harvard. edu). In this study, menopausal status was estimated by age <51 years (premenopausal) and ≥51 years (post-menopausal) of age. In a subset of each age group, we verified a difference in menopausal status by estradiol and follicle-stimulating hormone levels. Women on hormonal contraceptives or hormone replacement therapy were excluded. Hormones and electrolytes in serum and urine were measured in the Brigham and Women's Hospital's Research Assay Core Laboratory as previously reported. [18] [19] [20] Details are included in the online-only Data Supplement.
Clinical Statistical Analyses
Baseline analyses included Student t test and χ
2
. Continuous variables are presented as mean±SD or mean±SEM. Categorical variables are presented as a percentage of the total sample. Normal distribution of dependent variable was tested using Shapiro-Wilk test. Logarithmic transformation was performed for variables that were not normally distributed. The nominal P value was adjusted to 0.01 because of multiple comparisons. All statistical analyses were performed using STATA 14.1, adjusting for the following confounders: disease state (normotensive or hypertensive), age, sex, site, serum cortisol, PRA, serum potassium (K + ), and urinary K + excretion. The adjustments differed based on the primary end points being assessed as noted below. These covariates (fixed effects) were chosen for their clinical importance and significance in univariate analysis whereas identity was the random effect. Multiple linear regression was used to analyze the relationship between primary end points (eg, salt sensitivity of BP) and biological sex. For salt sensitivity of BP and renal plasma flow (RPF), the regression was adjusted for known cardiovascular risk factors (age, body mass index, disease state [hypertensive or normotensive], and race) and site. For analyses of the relationship between aldosterone and sex, 4 more adjustments were added: plasma cortisol (surrogate for adrenocorticotropic hormone), PRA, serum K + , and urine K + . In addition, in all subjects where the variables were available, we performed an interaction analysis between sex and aldosterone on systolic BP where the data were obtained under the similar conditions. To maximize the potential to see an effect, we used data obtained from a stress test: restricted salt diet, supine, and in response to an AngII infusion. The aldosterone component was dichotomized by using the median aldosterone increments (16.1 ng/dL). Systolic BP response to AngII was the dependent variable using the same adjustments as noted above. We also compared female and male subjects using Propensity Score analyses (STATA PSMATCH2). We used this approach to allow us to assemble female and male study populations that are balanced on the baseline covariates of age, race, body mass index, site, and disease state.
Rodents
Male and female Wistar rats were maintained on a liberal salt diet and water ad libitum. As previously reported, injury was caused by treating rats with an inhibitor of NO synthase, N ω -nitro-l-argininemethyl-ester (L-NAME), for 14 days, plus AngII on days 11 through 14. 21, 22 Adrenal glands were excised during euthanization, and adrenal zona glomerulosa (ZG) cells were isolated as previously reported. 23 Details are included in the online-only Data Supplement.
Results
Increased Salt Sensitivity of BP in Women Compared With Men
In the HyperPATH cohort, women and men had similar mean age, body mass index, PRA, serum K + , and urinary aldosterone (Table S1 ). Admission BP, serum cortisol, serum aldosterone, upright PRA, and urinary sodium and K + excretion were higher among men. However, salt sensitivity of BP was greater in female than males (adjusted β=+3.40; 95% confidence interval, 1.85, 4.94; Figure 1A ). This difference was evident even when subjects were stratified by hypertension status ( Figure 1B ) or those ≥51 years of age or <51 years of age ( Figure 1C ). These differences in BP responses to salt intake maybe due, in part, to alterations in adrenal or renal vascular responses to RAAS activation. 24 Although we used age as a surrogate for menopausal state, hormonal data support this conclusion. In a subgroup analyses, the older women had greater follicle-stimulating hormone levels (54.8±3.2 versus 14.3±1.8 mIU/mL) and lower estradiol levels (30.4±7.0 versus 58.7±4.8 pg/mL) than the younger women group.
Sex Affects Aldosterone Regulation, Renal Vascular Hemodynamics, and BP Responses to Acute RAAS Activation in Human Subjects
To begin to understand the mechanism for sex differences in salt sensitivity of BP, we compared the acute aldosterone responses to AngII infusion in males versus females in our cohort. In response to AngII, the adrenal gland produces and releases the steroid hormone aldosterone, which can be measured in the serum. Sex exerted a strong influence on adrenal responsiveness to AngII (Figure 2 ) both in subjects maintained on a liberal salt diet or after a restricted salt diet (Figure 2A and 2B) with women having significantly greater aldosterone responses on both. When stratified by age, the sex difference was evident only in subjects <51 years of age, regardless of salt intake, with younger women having a significantly greater aldosterone response than younger men ( Figures S2 and S3 ). However, this difference between men and women disappeared in subjects ≥51 years of age where the aldosterone responses were similar. We also studied RPF response to AngII infusion in our cohort. RPF response to AngII was greater in women than men on a liberal salt diet ( Figure 3A ). This sex difference was amplified when subjects were salt restricted ( Figure 3B ). As with the adrenal response, the differences between men and women were not evident in subjects ≥51 years of age where the RPF responses were Figure 1 . A, Women have increased salt sensitivity of blood pressure (BP) when compared with men. Salt sensitivity=baseline systolic BP (SBP) on a liberal salt diet-baseline SBP on a restricted salt diet. B, Salt Sensitivity of BP is higher in women than men in both hypertensive and normotensive state. C, Salt sensitivity of BP increased with age in both males and females, but the females still had significantly greater salt-sensitive BP than males regardless of age. The P values are from multiple linear regression models that were adjusted for age, sex, body mass index, site, and disease state. Values represent the means±SEM. A propensity score was also calculated for the total population (coefficient=3.12; P=0.001; 95% confidence intervals=1.21, 5.02). similar in both sexes ( Figure S4 ). We then studied systolic BP responses to AngII in our cohort. Women had similar BP rise in response to AngII infusion when compared with men on both restricted salt ( Figure S5 ) or liberal salt diets. However, sex differences in the BP responses to AngII were evident when stratified by age and by hypertensive versus normotensive subjects (Figure 4) . Specifically, hypertensive women had greater BP responses to AngII than men in both age groups. In contrast, normotensive women <51 years of age had lower BP responses to AngII than did men, a difference that disappeared in subjects ≥51 years of age where the BP responses were similar in both sexes while young normotensive males had a greater response than young females to AngII. Interaction between sex and aldosterone on systolic BP was also assessed. This analysis was performed using data where both BP and aldosterone were stressed. The stress test was the aldosterone and BP response to AngII infusion on a restricted salt diet. The aldosterone levels were dichotomized above and below the median of the increment in aldosterone in response to AngII (16.1 ng/dL). In the fully adjusted model, there was a significant interaction (P=0.003) between sex and aldosterone on the systolic BP response to AngII as documented in Figure 4 . Finally, propensity scores were calculated on the data in Figures 1 to 4 to test for equivalency in the 2 sex groups. The differences between the sexes were still highly significantly different as documented in the figure legends.
Rodent Studies
Mechanism Responsible for the Sex Difference
To characterize the differential effects of AngII on aldosterone levels in women versus men, we then turned to an isolated rat adrenal ZG cell preparations. Aldosterone levels basally and in responses to AngII and K + were significantly greater in females than males ( Figure 5 ). Furthermore, 24-hour urine aldosterone levels were significantly greater (P<0.05) in females (1.1±0.1 ng) than males (0.6±0.1 ng). These data support our hypothesis that females produce more aldosterone than males and . Systolic blood pressure (SBP) responses to angiotensin II (AngII) increased with age and are higher in women than men in hypertensive group on a salt-restricted diet while in normotensive group only women with age <51 y old have higher response than men. Interaction analyses between aldosterone and sex on SBP response to AngII in the total population was shown to be highly significant (coefficient=−7.41; P=0.003; 95% confidence interval [CI]=12.24, 2.57). The P values are from multiple linear regression models that were adjusted for age, sex, body mass index, site, and disease state. For the interaction analyses, the same adjustments were made except for sex. Values represent the means±SEM. A propensity score was also calculated for the total population (coefficient=5.13; P<0.001; 95% CI=3.14, 7.13).
thereby have an increased risk of aldosterone-mediated cardiovascular and renal damage.
Cardiac and Renal Damage
We have previously reported that in the L-NAME/AngII rat model, MR blockade prevents the cardiovascular and renal damage, suggesting that an inappropriately activated MR is the principle mechanism even though the aldosterone levels are not increased. 21, 22 Thus, we assessed the effect of sex on the level of damage. Sex-based comparisons revealed greater cardiac and renal damage in female compared with male rats as measured by myocardial necrosis and renal protein excretion, respectively ( Figure 6A and 6B) .
These sex differences in end-organ damage were not secondary to female rats receiving more L-NAME/AngII (males and females weighed the same) nor to differences in BP (male and female rats had similar BPs responses to treatment; Figure 6C ). However, the aldosterone response to L-NAME/AngII was significantly greater in the female compared with the male rats ( Figure 6D ). Furthermore, cardiac injury and proteinuria were reduced to the same extent in male and female rats in animals treated with eplerenone ( Figure 6A and 6B).
Discussion
Our human and animal data support the hypothesis that females, regardless of menopausal and disease status, will have greater salt sensitivity of BP than men and that the primary mechanism underlying this difference is altered aldosterone production. Women, whether young or old, hypertensive or normal, had a significantly greater degree of salt sensitivity of BP than men. Furthermore, the mechanisms underlying these differences are likely secondary to differences in 2 major sodium/volume modulating mechanisms-the kidney and aldosterone responses. Both vascular (as estimated by RPF) and aldosterone responses to stimulation with AngII in humans and aldosterone responses to AngII and K + in adrenal ZG cells and AngII in vivo in rats are greater in females than males. Finally, the potential pathophysiologic significance of these findings is exemplified by the greater degree of cardiovascular and renal damage in females observed in the L-NAME/AngII rodent model that was largely prevented by MR blockade.
Salt sensitivity of BP increased with age in both men and women in our cohort, confirming reports by others. 25 However, we observed that salt sensitivity of BP was greater in women than men in both young and older individuals. Our results extend previous reports in young black women, the DASHSodium trial (The Dietary Approaches to Stop Hypertension) and the GenSalt Chinese cohort study. [26] [27] [28] Each of these studies suggested that women had greater salt sensitivity of BP than men. [26] [27] [28] We, and others, have shown that increased salt intake leads to increased RPF, a relationship that is lost in salt-sensitive forms of hypertension. 24, 29 We explored whether RPF response to AngII would be affected by sex and found significant differences in our cohort. This would suggest that RAAS-mediated renal vascular hemodynamics might contribute to salt sensitivity of BP and CVD among women.
Sex differences in BP levels have been reported previously in rodents. A recent review by Blenck et al 30 summarized the literature in hypertensive rats. In 3 different L-NAME/AngII models, BP was higher in males in one, higher in females in another, and no difference in a third. In studies of spontaneously hypertensive rats, males have higher BP than females. 30 In addition, Xue et al 31 reported that chronic AngII increases BP to a higher level in male than female mice. However, in agreement with our findings, Sartori-Valinotti et al 32 reported that female rats had greater BP-lowering response to angiotensin converting enzyme inhibition and greater response to chronic AngII infusion than did male rats. In addition, Calhoun et al 33 reported that male Wistar Kyoto rats have lower BP than aged-matched female rats. There are differences between Xue et al's 31 study and ours that could account for these differences-Xue's study used mice not rats, and the mice were gonadectomized.
Sex differences in aldosterone/MR activation also have been reported in preclinical rodent models. In contrast to our results, Macova et al 34 and Wang et al 35 reported that estrogen treatment reduces adrenal and circulating aldosterone levels. However, ovariectomy did not change aldosterone levels in either model and Wang et al's used the mRen2.Lewis rat. 35 Studies in stroke-prone spontaneously hypertensive rats show that ovariectomy reduced strokes and renal injury while estrogen replacement restored damage. 36 In addition, in aged hypertensive mRen2.Lewis rats, ovariectomy reduced proteinuria and renal injury on a high-salt diet. 37 Furthermore, there is evidence that estrogen increases heart damage in both lean and obese ovariectomy dahl salt-sensitive rats. 38 These results suggest that in models of volume-sensitive hypertension, estrogen may promote rather than prevent cardiovascular damage.
What are the potential mechanisms that underlie our findings? Several mechanisms may be involved. First, we have reported that MR and estrogen receptor (ER)-α are part of a protein complex in cells that is necessary for ER-α inhibition of MR-mediated transcription. 39 Second, we recently documented that via a novel rapid-short negative feedback loop, MR activation of isolated adrenal ZG cells was associated with reduced aldosterone secretion. 40 We posit that ER-α blocks the MR and disrupts the short negative feedback loop leading to increased aldosterone secretion by ZG cells. These findings are consistent with our observations that isolated ZG cells from female rats have greater baseline and agoniststimulated aldosterone secretion than ZG cells isolated from aged-matched male rats. Furthermore, these studies are consistent with our data showing that women had greater in vivo AngII-stimulated aldosterone production than men. Last, we observed important end-organ consequences of the biological sex differences in aldosterone (eg, greater cardiac and renal damage in female than male rats). Third, regarding younger individuals, aldosterone may also be involved in those premenopausal women who do develop hypertension. We recently documented that polymorphic variants in the ER are associated with increased salt-sensitive BP but only in premenopausal females and not in men or postmenopausal females. 41 Thus, even in young women, those who develop hypertension likely may have it mediated by disordered aldosterone.
Our results suggest that women may derive more clinical benefit than men from therapeutic MR blockade. Clinical trials to assess this hypothesis are needed as we and others [42] [43] [44] [45] are unaware of clinical trials specifically designed to determine whether the clinical response to MR blockade differs by sex. [42] [43] [44] [45] [46] However, the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) provided an opportunity to assess the impact of sex on BP responses to MR blockade in 1411 participants who received MR blockade as a fourth line antihypertensive agent. 43 Again, this trial was not specifically designed to test the impact of biological sex. In ASCOT, women had significantly greater decreases in diastolic BP as compared with men, a result that is consistent with our findings. In addition, post hoc analyses of the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival) trial 42 data showed that MR blockade significantly decreased all-cause mortality in women, but not men; however, a direct comparison of the effect of sex showed no statistical difference. These results highlight the need for trials to assess the impact of sex on the clinical responses to MR blockade. Thus, our results are important because they provide the scientific rationale for such trials.
This study is likely the largest (1592 subjects) that has assessed the effect of biological sex on changes in BP and aldosterone in response to substantial, fixed changes in salt intake and their acute responses to AngII. Of importance, we controlled several environmental variables that could confound the interpretations of these results. Our studies were performed under standardized conditions of time of day, fixed sodium intake, withdrawal of interfering BP medications, and overnight supine posture as previously documented. 18, 19 However, there are limitations to our study. First, even though the human population was one of the largest reported of aldosterone/MR activation and the study design tightly controlled many critically important variables, this report still was a cross-sectional observational study. Thus, the cause and effect relationship to BP, aldosterone, and RPF is limited by study design. Second, in our rodent studies, we did not measure RPF nor did we assess the cause and effect relationships in other animal models of RAAS activation. Third, recent studies by Caroccia et al 47, 48 showed that in the adrenocortical carcinoma cell line, HAC15 that express ER-α, -β, and GPER-1 (G protein-coupled estrogen receptor), estrogen treatment did not affect aldosterone production. Yet, simultaneous blockade of ER-α and -β in these cells revealed the existence of a GPER-1-sensitive estrogenstimulated aldosterone production pathway. However, the in vivo and pathophysiological effects of this pathway have not been described, and we did not assess the potential effects of GPER-1 in our studies. Fourth, progesterone is known to act as an aldosterone antagonist. However, because the difference between men and women persists after the age of 51 years when progesterone levels are low in women, this does not seem to be a confounding factor. Fifth, to directly compare the responses in younger versus older men to those in women, an age cutoff of 51 years was used because this is the mean age of menopause in American women. Estradiol/follicle-stimulating hormone levels would have been informative to stratify for menopausal status but were not available for most of the subjects.
Perspectives
The present study shows evidence of chronic and acutely increased aldosterone/MR activation in female human and rats when compared with males. In the present study, these sex differences were present in both hypertensive and normotensive subjects, suggesting that the differences in aldosterone may predispose women, compared with men, to aldosterone-mediated CVD. This assumption was supported by a positive interaction between aldosterone and sex on systolic BP response to AngII. Finally, because the differential effect was present even in older individuals, it is likely that the difference is not mediated simply by differences in estrogen levels per se.
• Sex and aldosterone significantly interact to modify blood pressure.
• Female versus male rats have increased aldosterone production, myocardial damage, and proteinuria, which are prevented by mineralocorticoid receptor blockade.
What Is Relevant?
• Salt sensitivity of blood pressure is a risk factor for cardiovascular morbidity and mortality.
• Differences in aldosterone levels may predispose women to greater salt sensitivity of blood pressure and cardiovascular damage.
Summary
Females have greater evidence of cardiovascular damage mediated, in part, by increased aldosterone levels supporting the hypothesis that chronic and acute aldosterone production may contribute to sex differences in the incidence cardiovascular diseases.
Novelty and Significance
